产品封面图
文献支持

Ultra-LEAF™ Purified 抗人 CD314

(NKG2D) 抗体
收藏
  • ¥3300 - 8500
  • 齐源
  • 320813
  • 国产/进口
  • 2025年07月12日
  • FC, IP, FA
  • 小鼠
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 供应商

      齐源

    • 库存

      999

    • 靶点

      CD314 (NKG2D)

    • 级别

      CD314 (NKG2D) Antibody

    • 目录编号

      CD314 (NKG2D) Antibody

    • 克隆性

      单克隆

    • 抗原来源

      小鼠

    • 保质期

      CD314 (NKG2D) Antibody

    • 抗体英文名

      Ultra-LEAF™ Purified anti-human CD314 (NKG2D) Antibody

    • 抗体名

      CD314 (NKG2D) Antibody

    • 标记物

      CD314 (NKG2D) Antibody

    • 宿主

      小鼠

    • 适应物种

    • 免疫原

      CD314 (NKG2D) Antibody

    • 亚型

      CD314 (NKG2D) Antibody

    • 形态

      CD314 (NKG2D) Antibody

    • 应用范围

      FC, IP, FA

    • 保存条件

      2-8℃

    • 浓度

      CD314 (NKG2D) Antibody

    • 规格

      100 µg/ 1 mg

    规格:100 µg产品价格:¥3300.0
    规格: 1 mg 产品价格:¥8500.0
    Ultra-LEAF™ Purified anti-human CD314 (NKG2D) Antibody详细如下:

    Description :CD314 is a homodimeric C-type lectin-like protein also known as NKG2D. It is expressed on NKcells, CD8 T cells, γ/δ T cells, and in vitro induced LAK cells. Several molecules have beenidentified as the ligands for NKG2D, including MHC class-I chain-related protein A (MICA),MICB, and UL16-binding proteins (ULBPs). NKG2D has no intrinsic signaling capacity, butattains this by non-covalent association with DAP10 or DAP12 adaptors. In addition to being aprimary activation receptor on NK cells, NKG2D is also a costimulatory receptor for TCRmediated T cell proliferation and cytokine production. The interaction of NKG2D with its ligandsplays a role in the immune surveillance against pathogen and tumor cells, and in thepathogenesis of autoimmune diseases.

    Verified Reactivity :Human

    Reported Reactivity :African Green, Baboon, Cynomolgus, Rhesus

    Antibody Type :Monoclonal

    Host Species :Mouse

    Formulation :0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxinlevel is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.

    Preparation :The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

    Concentration :The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentrationand expiration, please enter the lot number in our Certificate of Analysis online tool.

    Storage & Handling :The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™solution contains no preservative; handle under aseptic conditions.

    Application :FC - Quality tested、IP, FA - Reported in the literature, not verified in house

    Recommended Usage :Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤2.0 µg per million cellsin 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated foroptimal performance for each application.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    Application References(PubMed link indicatesBioLegend citation):

    1. Wu J, et al. 1999. Science 285:730.

    2. Wu J, et al. 2000. J. Exp. Med. 192:1059.

    3. Groh V, et al. 2001. Nature Immunol. 2:255.

    4. Wu J, et al. 2002. J. Immunol. 169:1236.

    5. Roberts A, et al. 2001. J. Immunol. 167:5527.

    6. Groh V, et al. 2003. Proc. Natl. Acad. Sci. USA 100:9452.

    7. Kraetzel K et al. 2008. Eur. Respir. J. 32:563. PubMed

    8. Correia DV, et al. 2011. Blood 118:992. (FC) PubMed

    9. Watanbe M, et al. 2014. Int Immunol. PubMed

    Product Citations:

    1. Breman E, et al. 2019. Front Immunol. 9:2940. PubMed

    2. Thrash EM, et al. 2020. STAR Protoc. 1:100055. PubMed

    3. Dudek M, et al. 2021. Nature. 592:444. PubMed

    4. Van der Meer JMR, et al. 2021. Oncoimmunology. 10:1981049. PubMed

    5. Glasner A, et al. 2017. Sci Rep. 7:40944. PubMed
    相关实验
    • CD3/CD28 做好 T 细胞激活与扩增

      7211011 小鼠淋巴细胞分离液 达优 100339 Ultra-LEAF Purified anti-mouse CD3ε Antibody BioLegend 102115 Ultra-LEAF Purified anti-mouse CD28 Antibody BioLegend   CD3/CD28 Streptamer® 多聚体法:   货号 名称

    • 以单克隆抗体为基础的免疫治疗

      临床验证。抗人CD20(Rituximab)是第1个为FDA批准可用于临床癌症治疗的单抗。Rituximab与细胞表面的CD20分子结合后,可通过诱导ADCC和CDC清除高表达CD20分子的恶性B细胞,从而被认为在低分化的B细胞淋巴瘤和非霍奇金淋巴瘤的治疗中起重要作用。       近年来,另一个备受人们关注的治疗性单抗是抗Her-2的抗体。Her-2是表皮生长因子受体(EGFR)成员,参与乳腺癌的发生,且与乳腺癌患者的预后有关。相应单抗与Her-2结合可阻止Her-2与相应的生长因子的结合,抑制乳腺

    • 嵌合抗CD20Fab’抗体片段诱导Raji 细胞的凋亡机制

      CD20抗体Fab’片段,并在大肠杆菌中高效可溶性分泌表达[ 8 ] ,本研究的目的在于研究嵌合抗CD20Fab’片段的抗肿瘤活性及其作用机制。一、材料和方法1、材料MTT购自Sigma公司;Annexin-V为宝灵曼公司试剂盒;TRIZOL RNA提取试剂盒为美国Gibco公司产品;兔抗人bcl-2单克隆抗体和辣根过氧化物酶标记的羊抗兔IgG为北京中山生物技术有限公司产品,嵌合抗CD20Fab’片段为我室表达并纯化。β-actin引物(上游:5-TCATGTTTGAGACCTTCAA-3,下游

    图标技术资料

    需要更多技术资料 索取更多技术资料

    资料下载:

    320813.pdf 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥9020
    北京达科为生物技术有限公司
    2023年12月26日询价
    ¥500
    北京百奥创新科技有限公司
    2025年07月09日询价
    ¥4900
    上海齐源生物科技有限公司
    2025年07月13日询价
    询价
    艾美捷科技有限公司
    2025年07月07日询价
    询价
    上海西格生物科技有限公司
    2025年12月19日询价
    文献支持
    Ultra-LEAF™ Purified 抗人 CD314 (NKG2D) 抗体
    ¥3300 - 8500